Robert W. Baird Issues Positive Forecast for Axsome Therapeutics (NASDAQ:AXSM) Stock Price

Key Points

• Robert W. Baird raised its price target on Axsome from $241 to $246 and kept an "outperform" rating (implying ~9.8% upside), while broker consensus is a Moderate Buy with an average target of $243.
• Axsome reported Q1 revenue of $191.2M, up ~57% year‑over‑year driven by Auvelity ($153.2M) and Sunosi ($33.9M), but missed EPS at -$1.26 versus a -$0.85 consensus, leaving the company unprofitable.
• Insiders sold 67,878 shares (~$11.12M) in the last 90 days yet still own 22.3% of the stock, and institutional investors hold about 81.49% with several large funds increasing their positions.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) had its price target lifted by equities researchers at Robert W. Baird from $241.00 to $246.00 in a report released on Tuesday, MarketBeat reports. The brokerage presently has an "outperform" rating on the stock. Robert W. Baird's target price indicates a potential upside of 9.81% from the company's current price.

A number of other analysts have also recently commented on the company. Wolfe Research began coverage on Axsome Therapeutics in a research report on Monday, February 23rd. They issued an "outperform" rating and a $230.00 price target on the stock. UBS Group raised their price objective on Axsome Therapeutics from $251.00 to $259.00 and gave the company a "buy" rating in a research report on Friday, April 10th. Cantor Fitzgerald reissued an "overweight" rating and issued a $272.00 target price on shares of Axsome Therapeutics in a report on Monday. Royal Bank Of Canada increased their target price on Axsome Therapeutics from $219.00 to $222.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 24th. Finally, Needham & Company LLC raised their price target on Axsome Therapeutics from $225.00 to $255.00 and gave the company a "buy" rating in a report on Friday. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $243.00.

Axsome Therapeutics Stock Up 8.5%

Shares of Axsome Therapeutics stock opened at $224.03 on Tuesday. Axsome Therapeutics has a 1 year low of $96.09 and a 1 year high of $234.29. The firm has a market cap of $11.52 billion, a price-to-earnings ratio of -60.71 and a beta of 0.59. The company has a 50-day moving average of $170.95 and a 200 day moving average of $162.68. The company has a debt-to-equity ratio of 1.38, a current ratio of 1.55 and a quick ratio of 1.48.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its quarterly earnings data on Monday, May 4th. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.41). The business had revenue of $191.20 million for the quarter, compared to the consensus estimate of $191.10 million. Axsome Therapeutics had a negative return on equity of 232.61% and a negative net margin of 28.69%.Axsome Therapeutics's quarterly revenue was up 57.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Axsome Therapeutics will post -1.06 earnings per share for the current fiscal year.

Insider Transactions at Axsome Therapeutics

In other news, COO Mark L. Jacobson sold 35,378 shares of the firm's stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $161.88, for a total value of $5,726,990.64. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Mark Coleman sold 25,000 shares of Axsome Therapeutics stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $161.11, for a total value of $4,027,750.00. Following the completion of the sale, the director directly owned 47,140 shares of the company's stock, valued at $7,594,725.40. The trade was a 34.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 67,878 shares of company stock worth $11,122,891 in the last ninety days. Insiders own 22.30% of the company's stock.

Institutional Investors Weigh In On Axsome Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in AXSM. Vanguard Group Inc. boosted its holdings in shares of Axsome Therapeutics by 6.0% in the third quarter. Vanguard Group Inc. now owns 4,180,646 shares of the company's stock worth $507,739,000 after buying an additional 235,626 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Axsome Therapeutics by 45.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,509,870 shares of the company's stock valued at $275,763,000 after buying an additional 472,422 shares during the last quarter. Wellington Management Group LLP increased its holdings in Axsome Therapeutics by 84.1% during the third quarter. Wellington Management Group LLP now owns 1,334,560 shares of the company's stock valued at $162,082,000 after buying an additional 609,516 shares during the last quarter. Invesco Ltd. raised its position in Axsome Therapeutics by 28.6% in the fourth quarter. Invesco Ltd. now owns 1,273,494 shares of the company's stock worth $232,591,000 after acquiring an additional 282,937 shares during the period. Finally, Geode Capital Management LLC raised its position in Axsome Therapeutics by 1.3% in the fourth quarter. Geode Capital Management LLC now owns 1,010,249 shares of the company's stock worth $184,544,000 after acquiring an additional 12,549 shares during the period. Hedge funds and other institutional investors own 81.49% of the company's stock.

More Axsome Therapeutics News

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Q1 revenue beat and strong year-over-year growth: Net product revenue was $191.2M (vs. $191.1M consensus) and up ~57% year-over-year, driven by Auvelity ($153.2M) and Sunosi ($33.9M). This supports continued commercial momentum across core products. Read More.
• Positive Sentiment: Regulatory and pipeline progress: Auvelity received an approval for agitation associated with dementia due to Alzheimer’s disease, and Axsome submitted an NDA for AXS‑12 (cataplexy). The company also added AXS‑20 (PDE10A inhibitor) to the pipeline—these expand addressable markets and future revenue potential. Read More.
• Positive Sentiment: Analyst/broker tone and investor engagement: Broker consensus is a “Moderate Buy,” and management will be participating in multiple investor conferences in May (BofA, fireside chat, etc.), which can boost visibility and help reprice expectations. Read More. Read More.
• Neutral Sentiment: Company events and disclosures: Management hosted a conference call and published a slide deck and transcript; analysts will parse details on unit trends and cost trajectory during conference appearances. Read More.
• Negative Sentiment: EPS miss and continued losses: Reported EPS was a loss of $1.26 vs. consensus -$0.85 (miss), and the company remains unprofitable with negative margins and ROE metrics—this leaves valuation sensitive to execution. Read More.
• Negative Sentiment: Mixed product trends flagged by analysts: Despite strong YoY growth, some analysts note sequential declines in Auvelity and Sunosi sales and call management’s peak revenue targets ambitious, which could limit upside if sustained. Read More.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome's pipeline includes several late-stage and approved product candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.